Droxidopa
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
- Droxidopa
- Droxidopa: From Neurogenic Orthostatic Hypotension to Variably Protease-Sensitive Prionopathy
Droxidopa: From Neurogenic Orthostatic Hypotension to Variably Protease-Sensitive Prionopathy
One-Sentence Summary
Droxidopa is a synthetic amino acid precursor known pharmacologically to be converted into norepinephrine, with clinical use in neurogenic orthostatic hypotension (official original-indication data is not available in this Evidence Pack). The TxGNN model predicts it may be effective for Variably Protease-Sensitive Prionopathy (VPSPr), but this prediction is currently supported by 0 clinical trials and 0 publications — it is a model-score-only signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Neurogenic orthostatic hypotension (based on known pharmacology only; TFDA-approved indication text unavailable — drug is not marketed in Taiwan) |
| Predicted New Indication | Variably Protease-Sensitive Prionopathy |
| TxGNN Prediction Score | 99.33% |
| Evidence Level | L5 |
| US Market Status | Not Marketed (未上市) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, droxidopa is a synthetic amino acid precursor that is converted by DOPA decarboxylase into norepinephrine, and its clinical use has centered on neurogenic orthostatic hypotension, an autonomic/neurovascular condition.
VPSPr is a rare, atypical prion disease characterized by variable protease-sensitivity of misfolded prion protein and progressive neurodegeneration. There is no established or biologically inferable mechanistic link between norepinephrine-precursor pharmacology and prion protein misfolding pathology.
The evidence pack’s own rationale flags this explicitly: the high TxGNN score (0.993) most likely reflects a topological artifact in the knowledge graph — droxidopa and VPSPr may simply share proximity to “neurodegenerative disease” nodes — rather than genuine pharmacological plausibility. With no original-indication data, no MOA data, no trials, and no literature available to cross-validate, this mechanistic link should be treated as speculative and low-confidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate rests entirely on a single TxGNN model score with no clinical trial, literature, original-indication, or MOA data to corroborate it. The evidence pack itself assesses the mechanistic link as likely a graph-topology artifact rather than a pharmacologically plausible signal, so it does not meet the bar to advance.
To proceed, the following is needed:
- Confirmed original indication and detailed mechanism of action (MOA) for droxidopa
- TFDA/original-market label warnings and contraindications (currently a Blocking data gap for safety screening)
- Independent preclinical or mechanistic evidence linking noradrenergic pathways to prion protein pathology, before any trial or literature search is expected to be productive
- Re-evaluation of the TxGNN graph signal to rule out topological bias before further investment
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.